MarginsXMarginsX
Home › Markets › Health Care › NERV

Minerva Neurosciences Inc (NERV)

NERV trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.20
-4.35% on the day
Market cap
$109.6M
Micro cap
Revenue · 2024
$0
Prior year not contiguous
Net income · 2024
$1.4M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1598646/000095017025026055/0000950170-25-026055-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerNERV on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001598646
SEC industry codePharmaceutical Preparations
Incorporated inMA

Financials · 2024

LineValue
Revenue$0
Net income$1.4M
Operating income-$21.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$21.4M
Total assets$37.1M
P/E (computed)76.2×
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
7.7 months
$20.2M cash at September 30, 2026
Share count, 1 year
+612.6%
2025-10-31 to 2026-11-03 · +612.6% over 3 years
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$20.2M cash; operating cash flow -$7.9M a quarter.Report 2026-09-30
Shares outstanding49,835,241 (2026-11-03); 6,993,406 a year earlier; 6,993,406 three years earlier.Cover page 2026-11-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-05-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed$100.7M-$8.1M$20.2MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2026
2026-06-30
Not filed$17.5M-$13.3M$24.7MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q1 2026
2026-03-31
Not filed-$125.4M-$5.4M$32.7MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q4 2025
2025-12-31
Not filed-$283.7M-$4.5M$82.3MNo debt tagsNeeds four quarters10-K 2026-03-11
Q3 2025
2025-09-30
Not filed-$2.7M-$2.9M$12.3MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2025
2025-06-30
Not filed-$3.3M-$2.0M$15.2MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q1 2025
2025-03-31
Not filed-$3.8M-$4.1M$17.3MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q4 2024
2024-12-31
Not filed-$4.3M-$5.2M$21.4MNo debt tags$010-K 2026-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-27
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 650 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.0%
1 month-8.5%
3 months-41.3%
Year to date-42.8%
1 year-40.3%
From 52-week high-71.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
OKUROnKure Therapeutics Inc.$2.75+4.56%$111.4M
CATXPerspective Therapeutics Inc.$0.9238-2.05%$111.6M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M
ADAGAdagene Inc.$1.60-6.43%$105.7M
IMUXImmunic Inc.$7.23-3.86%$114.8M
CLLSCellectis S.A.$1.04-11.86%$104.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier